Feebris Proven to Save the NHS £0.5m per 1,000 Patients Annually in New, Independent Study

Feebris Proven to Save the NHS £0.5m per 1,000 Patients Annually in New, Independent Study

Feebris Proven to Save the NHS £0.5m per 1,000 Patients Annually in New, Independent Study

·      The study was commissioned by the NHS Innovation Accelerator and conducted by the York Health Economics Consortium

·      It looked at the use of Feebris across 1,000 patients in North-East London

·      It demonstrated significant savings from reductions in A&E visits and avoidable hospitalisations

·      If scaled across older adults in care homes alone, Feebris could generate over £200m in savings

London,UK, [5 October 2023]: A new study conducted by the York Health Economics Consortium (YHEC) has demonstrated substantial cost savings for the NHS thanks to the Feebris AI-guided virtual care platform.

The study evaluated the use of Feebris by the local Integrated Care System in North-East London across 1,000 patients, with a deployment supported by Care City, a non-profit innovation centre specialising in healthy ageing and regeneration, and Havering Health, a federation of 41 GP practices. The platform was deployed to expand clinical capacity and equip carers and clinical teams with the tools needed to spot early deterioration in patients in the community.

The YHEC analysis evidenced substantial savings of £500,000 per 1,000 patients over a one-year period resulting from reductions in avoidable deterioration, A&E visits and hospital admissions. The evaluation was carried out using pre-implementation data, which included the number of NHS 111 calls, ambulance callouts and conveyances.

The project evidenced the potential of the technology to create clinical capacity by empowering both care providers and patients with the ability to identify and manage health concerns early, thereby reducing complications and the need for hospital admission.

Unlike conventional remote monitoring tools, Feebris uses proprietary algorithms to ensure that anyone can capture clinically reliable information from diagnostic devices, reducing burden on clinicians. The technology helps clinicians prioritise patient lists according to risk, accelerating access to diagnosis and treatment for those most in need.

During a one-year period, the Feebris platform supported a 38% reduction in conveyances to A&E and a 25% reduction in hospital admissions. The study authors comment that the impact is likely to be underestimated, as the benefits for primary care, such as reductions in GP visits, could not be fully evaluated due to lack of data.

The platform could therefore generate over £200m in savings per year if scaled to support all residents in care homes across the UK, with the number estimated to be over 400,000.

Feebris is currently deployed in over 100 sites in the UK, working with Integrated Care Systems to support care homes, primary care facilities, community nursing and virtual wards.

Commenting on the study, Dr Elina Naydenova, CEO and Cofounder of Feebris, said:

“We are delighted by the findings of the York Health Economics Consortium study, which highlighted the significant savings that Feebris has helped deliver for the NHS. But beyond the immediate savings our technology can generate for the system, this is also an opportunity to advance integrated care by appropriately incentivising community management of health in order to reduce pressures on our hospitals and urgent care centres. Our technology supports the NHS in managing health risks across the population and ensuring patients in need of clinical attention are appropriately prioritised.

“We are extremely excited about the future as we continue to build on the success of this project, with more evaluations on the horizon in the coming months. The results are testament to the impact that Feebris is already making in supporting patients, carers and clinicians across the UK.”

In a statement, Konrad Dobschuetz, National Director of the NHS Innovation Accelerator, said:

“We are impressed by the impact the Feebris tool could provide in system at this crucial time. I am confident that this can further strengthen the opportunities for the company in their drive for adoption and scale across the wider healthcare system..”


Notes to editors

The Feebris system is comprised of: 

·     The Feebris kit, which includes a range of medical sensors for at-home monitoring of health.

·     The Feebris mobile application, which allows patients and carers alike to carry out clinical assessments, using decision-support algorithms to ensure universal quality, and escalate risks to the appropriate healthcare professionals.

·     The Feebris clinical portal, which allows healthcare professionals to access assessment data, risk-stratify patient lists and identify early deterioration.

The York Health Economics Consortium study can be accessed here.  

About Feebris

At Feebris, our mission is to create a world where nobody suffers because they cannot access healthcare. The Feebris AI-guided platform empowers a community user to conduct a clinically reliable check-up and assess risk, improving efficiency and quality of care at scale. Our system is currently deployed across over 100 sites in the United Kingdom.

For further information or to arrange an interview, please contact Leontina Postelnicu, Policy and Public Affairs Lead: leo@feebris.com.

The Companies In This Story

Feebris Logo

About Feebris


Feebris helps carers to identify health risks and deterioration within elderly communities. The Feebris app guides a carer through a 10min check-up, including capture of vital signs from connected medical-grade sensors (digital stethoscope, pulse oximeter etc.).

Powerful AI augments clinical guidelines and personalised monitoring to help decisions on triaging health issues. In care homes, Feebris can help carers triage the day-to-day health needs of their residents during the COVID-19 pandemic, and also enhance the capabilities of remote clinicians



About The Author



 at Feebris


More from Feebris

More Stories